Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870182 | 0.86 | POLB (0.43) | HPGDLMNASMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL17535603 | 0.81 | PDE10A (0.42) | HPGDLMNASMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL6868920 | 0.80 | HPGD (0.50) | HPGDLMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL27498565 | 0.80 | MTNR1A (0.41) | HPGDLMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1163625 | 0.78 | MAPK14 (0.44) | SMN1; SMN2RAB9ANPC1MAPTL3MBTL1 | |
| SCHEMBL16626806 | 0.77 | TUBB4A (0.38) | HPGDLMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8033888 | 0.77 | HPGD (0.49) | HPGDLMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20975261 | 0.77 | HPGD (0.60) | HPGDLMNASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16056355 | 0.76 | KDM4E (0.47) | HPGDLMNASMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL6862708 | 0.76 | KDM5A (0.36) | HPGDLMNASMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280796-B1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6703397-B2 | REACTING A NITRILE GROUP CONTAINING INDOLE DERIVEATIVE WITH GUANIDINE OR SALT; USEFUL AS PROHYLAXIS OR THERAPEUTICAL TREATMENT OF INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-06-26 | — | — | US | disclosed |
| EP-1280796-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083474-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | IDO1, IDO2, AANAT | HPGD 1619/4885LMNA 4705/4885SMN1; SMN2 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.